MS-20 on Patients With Ulcerative Colitis(UC)

  • STATUS
    Recruiting
  • End date
    Dec 4, 2023
  • participants needed
    40
  • sponsor
    National Taiwan University Hospital
Send
Updated on 4 July 2022
See if I qualify
microbiota

Summary

This is a small pilot study of the fermented soybean extract MicrSoy-20(MS-20) to confirm its ability to improve UC severity with the treatment of standard therapies.

The primary endpoint, structural alteration of gut microbiota during the trial will be analyzed. Secondary endpoints aim to observe the changes of partial Mayo score, patient response of medication of UC treatments, biomarker changes in blood, and safety after taking MS-20.

Details
Condition Ulcerative Colitis
Treatment Placebo, MS-20 oral solution
Clinical Study IdentifierNCT04908644
SponsorNational Taiwan University Hospital
Last Modified on4 July 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male or female subject aged between 20 and 65 years old who has confirmed diagnosis of moderate to severe Ulcerative Colitis (UC): partial Mayo score≧5
The subject must be informed and able to sign the informed consent form
Females with childbearing potential must agree to completely abstain from sexual intercourse or use adequate contraceptive methods such as IUD or birth control pills during the trial period. [Definition of infertility: (1) Menopause for at least 1 year; (2) Has undergone surgical ligation, such as hysterectomy, bilateral oophorectomy, or fallopian tube ligation; (3) Congenital structural abnormalities
Male subjects must agree to avoid donating sperm during the period of receiving the investigational product, and completely abstain from sexual intercourse or use appropriate contraceptive methods such as condoms
As judged by the investigators, subject who is proactive, have the ability to communicate with study staff, and capable and willing to cooperate two points below
be willing and able to comply with the subject visit arrangements and procedures defined in the protocol
to collect, store with adequate refrigerating facilities and delivery of stool samples from home

Exclusion Criteria

Subject who is allergic to soybean and its products
Subject who has a history of human immunodeficiency virus (HIV) infection. (Through oral disclosure and medical records by the doctor, subject who decline to disclose will be excluded)
Subject cannot take drugs orally or have any gastrointestinal history or surgery which investigator believes may affect the absorption of the oral investigational product
Subject who has received any immunoglobulin product or blood product within 3 months before the day of blood draw
Subject who has used antibiotics, antifungal or antiviral drugs (not including skin topical medication) within 30 days before the screening visit
Subject who has used probiotics and prebiotics-related products within 14 days before the screening visit (e.g., yogurt drink, yogurt, Yakult, Wakamoto tablets, Shin Biofermin S tablets, probiotic powder, fermented beverages, tablets, capsules, inulin, oligosaccharide products, etc.)
Subject who has used Chinese medicine or products containing such ingredients within 14 days before the screening visit
Subject who had diarrhea caused by gastrointestinal infections within14 days before the screening visit (more than three soft or watery stools within 24 hours) or those who had C. difficile infection
Woman who is pregnant, breastfeeding, or expect to breastfeed during the study period
Subject who has any of the following abnormalities of biochemical lab results: AST or ALT (> 3 × upper limit of normal [ULN]) or higher; Total bilirubin ≥ 1.5 x ULN; Serum creatinine> 2 × ULN
Subject who has a history of malignant tumors within five years before the screening visit, except for locally curable cancers that have been clearly cured, such as basal or squamous-cell carcinoma, superficial bladder cancer, or prostate, cervix, or breast carcinoma in situ
The subject has a medical history of drug or alcohol addiction that may result in the inability to complete the trial at the investigator's discretion
Subject who has participated in a clinical trial of other investigational drug treatments or medical devices within 30 days before the screening visit
Subject who has participated in a weight control program within 60 days before the screening visit
Subject who has been abroad for more than 10 days in the 30 days before the screening visit or expected to go abroad for more than 10 days during the trial period
The investigator judges that the subject is not suitable for participating in the trial
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

microbiota

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note